Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Stryker (SYK) and Genmab (GMAB)

Tipranks - Tipranks - Wed Apr 15, 6:29AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TransMedics Group (TMDX), Stryker (SYK) and Genmab (GMAB) with bullish sentiments.

Claim 30% Off TipRanks

TransMedics Group (TMDX)

Canaccord Genuity analyst William Plovanic maintained a Buy rating on TransMedics Group today and set a price target of $152.00. The company’s shares closed last Monday at $113.36.

According to TipRanks.com, Plovanic is a 3-star analyst with an average return of 1.1% and a 40.3% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as TriSalus Life Sciences, Edwards Lifesciences, and Irhythm Technologies. ;'>

Currently, the analyst consensus on TransMedics Group is a Moderate Buy with an average price target of $155.10, which is a 38.1% upside from current levels. In a report issued on April 1, TD Cowen also maintained a Buy rating on the stock with a $190.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Stryker (SYK)

Canaccord Genuity analyst Caitlin Roberts reiterated a Buy rating on Stryker today and set a price target of $435.00. The company’s shares closed last Monday at $347.24.

According to TipRanks.com, Roberts is a 1-star analyst with an average return of -5.7% and a 22.0% success rate. Roberts covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Zimmer Biomet Holdings, and Smith & Nephew Snats. ;'>

Stryker has an analyst consensus of Strong Buy, with a price target consensus of $425.10, which is a 24.7% upside from current levels. In a report released yesterday, Leerink Partners also initiated coverage with a Buy rating on the stock with a $410.00 price target.

Genmab (GMAB)

In a report released today, Eva Fortea Verdejo from Wells Fargo maintained a Buy rating on Genmab, with a price target of $40.00. The company’s shares closed last Monday at $28.20.

According to TipRanks.com, Verdejo is a 5-star analyst with an average return of 36.6% and a 75.9% success rate. Verdejo covers the Healthcare sector, focusing on stocks such as Bicara Therapeutics Inc., Kiniksa Pharmaceuticals, and Revolution Medicines. ;'>

Currently, the analyst consensus on Genmab is a Strong Buy with an average price target of $38.44, which is a 36.7% upside from current levels. In a report issued on March 30, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $30.00 price target.

Read More on TMDX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).